W
William G. Rice
Researcher at Emory University
Publications - 52
Citations - 3740
William G. Rice is an academic researcher from Emory University. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 19, co-authored 49 publications receiving 3250 citations. Previous affiliations of William G. Rice include University of Texas Health Science Center at San Antonio.
Papers
More filters
Journal ArticleDOI
Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis
Denis Drygin,Adam Siddiqui-Jain,Sean O'Brien,Michael K. Schwaebe,Amy M. Lin,Josh Bliesath,Caroline B. Ho,Chris Proffitt,Katy Trent,Jeffrey P. Whitten,John K.C. Lim,Daniel D. Von Hoff,Kenna Anderes,William G. Rice +13 more
TL;DR: CX-3543 is the first G-quadruplex interactive agent to enter human clinical trials, and it is currently under evaluation against carcinoid/neuroendocrine tumors in a phase II clinical trial.
Journal ArticleDOI
Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth
Denis Drygin,Amy M. Lin,Josh Bliesath,Caroline B. Ho,Sean O'Brien,Chris Proffitt,Mayuko Omori,Mustapha Haddach,Michael K. Schwaebe,Adam Siddiqui-Jain,Nicole Streiner,Jaclyn E Quin,Elaine Sanij,Megan J. Bywater,Ross D. Hannan,David M. Ryckman,Kenna Anderes,William G. Rice +17 more
TL;DR: Molecular studies demonstrate that CX-5461 inhibits the initiation stage of rRNA synthesis and induces both senescence and autophagy, but not apoptosis, through a p53-independent process in solid tumor cell lines.
Journal ArticleDOI
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Megan J. Bywater,Gretchen Poortinga,Gretchen Poortinga,Elaine Sanij,Elaine Sanij,Nadine Hein,Abigail Peck,Carleen Cullinane,Meaghan Wall,Leonie A. Cluse,Denis Drygin,Kenna Anderes,Nanni Huser,Chris Proffitt,Josh Bliesath,Mustapha Haddach,Michael K. Schwaebe,David M. Ryckman,William G. Rice,Clemens A. Schmitt,Clemens A. Schmitt,Scott W. Lowe,Ricky W. Johnstone,Ricky W. Johnstone,Richard B. Pearson,Grant A. McArthur,Ross D. Hannan +26 more
TL;DR: It is shown that rDNA transcription can be therapeutically targeted with the small molecule CX-5461 to selectively kill B-lymphoma cells in vivo while maintaining a viable wild-type B cell population.
Journal ArticleDOI
CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
Adam Siddiqui-Jain,Denis Drygin,Nicole Streiner,Peter C. Chua,Fabrice Pierre,Sean O'Brien,Josh Bliesath,Mayuko Omori,Nanni Huser,Caroline B. Ho,Chris Proffitt,Michael K. Schwaebe,David M. Ryckman,William G. Rice,Kenna Anderes +14 more
TL;DR: CX-4945 is the first orally bioavailable small molecule inhibitor of CK2 to advance into human clinical trials, thereby paving the way for an entirely new class of targeted treatment for cancer.
Journal ArticleDOI
The RNA Polymerase I Transcription Machinery: An Emerging Target for the Treatment of Cancer
TL;DR: Experimental data and potential strategies to downregulate rRNA synthesis and induce an antiproliferative response in cancer cells are discussed.